Nevertheless, the trial adds to growing evidence that next-generation incretin-based therapies may redefine diabetes treatment by targeting both blood sugar levels and the underlying metabolic factors that drive the disease
The review also noted that decreased GLP-1 secretion may contribute to obesity development, and that exaggerated secretion may be responsible for postprandial reactive hypoglycaemia
This triple mechanism of action distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
Novo Nordisk filed for FDA approval of CagriSema in early 2026, with a review decision expected later this year
This antioxidant has been found to improve glucose uptake and may enhance GLP-1 response through mitochondrial and insulin-signaling pathways
When you choose us for your Rybelsus treatment, youll receive a full spectrum of support that includes advanced blood work to monitor your metabolic health, detailed body composition analysis to track fat loss and muscle retention, and personalized nutritional counseling to ensure youre following a diet plan that promotes healthy, sustainable results
